RemeGen Co (SHSE:688331) Owner Earnings per Share (TTM): 1.90 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688331 RemeGen Co Ltd SHSE:688331
47 GF Score
Price ¥117.94
GF Value ¥241.90
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is RemeGen Co Owner Earnings per Share (TTM)?

RemeGen Co SHSE:688331 +2.81% 47 Owner Earnings per Share (TTM) is 1.90 as of Dec. 2025. GuruFocus rates SHSE:688331 with a GF Score™ of 47/100 and a GF Value™ of ¥241.90 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 213 Biotechnology companies, RemeGen Co ranks worse than 76.53% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

RemeGen Co's Owner Earnings per Share (TTM) ended in Dec. 2025 was ¥1.90. It's Price-to-Owner-Earnings ratio for today is 62.07.


The historical rank and industry rank for RemeGen Co's Owner Earnings per Share (TTM) or its related term are showing as below:

SHSE:688331' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 56.06   Med: 68.82   Max: 98.12
Current: 62.04


During the past 8 years, the highest Price-to-Owner-Earnings ratio of RemeGen Co was 98.12. The lowest was 56.06. And the median was 68.82.


SHSE:688331's Price-to-Owner-Earnings is ranked worse than
76.53% of 213 companies
in the Biotechnology industry
Industry Median: 23.62 vs SHSE:688331: 62.04

RemeGen Co's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was ¥2.12. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥10.44. It's PE Ratio (TTM) ratio for today is 11.30.

RemeGen Co's EPS without NRI for the six months ended in Dec. 2025 was ¥0.97. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was ¥9.28. It's PE Ratio without NRI ratio for today is 12.71.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


RemeGen Co Owner Earnings per Share (TTM) Related Terms


RemeGen Co Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Owner Earnings per Share (TTM) Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial 0.00 -4.94 -7.42 -8.25 1.32

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -8.25 0.00 1.32 0.00

SHSE:688331 vs VRTX, REGN, MRNA: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, RemeGen Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Price-to-Owner-Earnings falls into.


SHSE:688331
47GF Score
RemeGen Co Ltd SHSE:688331
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

RemeGen Co's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 710
Depreciation, Depletion and Amortization 320
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 539
Change In Working Capital 129
Shares Outstanding (Diluted Average) 550

1. Start with "Net Income" from income statement. RemeGen Co's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was ¥710 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. RemeGen Co's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2025 was ¥320 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. RemeGen Co's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = ¥539 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

RemeGen Co's 5-Year Average Maintenance Capital Expenditure = ¥539 Mil

5. "Change In Working Capital" is from cashflow statement. RemeGen Co's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 was ¥129 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. RemeGen Co's Shares Outstanding (Diluted Average) for the months ended in Dec. 2025 was 549.763 Mil.

RemeGen Co's Onwer Earnings Per Share for Dec. 2025 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 709.65 +319.677+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-538.578+128.931)/549.763
=1.90

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=117.94/1.90
=62.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 1.90 mean?
RemeGen Co (SHSE:688331) has a Owner Earnings per Share (TTM) of 1.90 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on RemeGen Co. According to the industry distribution chart, RemeGen Co ranks #163 out of 213 companies in the Biotechnology industry, placing it in the top 76.5%.
Is RemeGen Co's Owner Earnings per Share (TTM) too high?
RemeGen Co's current Owner Earnings per Share (TTM) is 1.90. The Biotechnology industry median Owner Earnings per Share (TTM) is 23.62. RemeGen Co's value of 1.90 is 92% below this industry median. Based on the distribution chart, RemeGen Co ranks #163 out of 213 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RemeGen Co has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Owner Earnings per Share (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #163 out of 213 companies for Owner Earnings per Share (TTM). This places RemeGen Co in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.62. RemeGen Co's value of 1.90 is 92% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 23.62, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Owner Earnings per Share (TTM) of 1.90 is 92% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on RemeGen Co. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 23.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Owner Earnings per Share (TTM) is 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (SHSE:688331) is currently considered Possible Value Trap. The stock's GF Value™ is ¥241.90, compared to a current price of ¥117.94 — trading 51.2% below its estimated fair value. The current Owner Earnings per Share (TTM) is 1.90 and 92% below the Biotechnology industry median of 23.62. RemeGen Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For RemeGen Co (SHSE:688331), the current Owner Earnings per Share (TTM) is 1.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (SHSE:688331) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of ¥117.94 is trading 51.2% below its estimated GF Value™ of ¥241.90. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for SHSE:688331:

  • Owner Earnings per Share (TTM): 1.90
  • GF Value™: ¥241.90 vs. price of ¥117.94 (51.2% below fair value)
  • GF Score™: 47/100 with 5 warning signs
  • Industry Position: 92% below the Biotechnology median (#163 of 213)

No single metric tells the full story. See the SHSE:688331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
47GF Score

Get the complete analysis for SHSE:688331

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥117.94
Price
¥241.90
GF Value